We found that targeting ETO-treated breast cancer cells with an ATM kinase inhibitor, KU-55933 (KU) induced higher chromosomal damage/aberrations, as evaluated by the cytokinesis-block micronucleus assay. The gene discussed is RUNX1T1; the disease is breast carcinoma.